Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Efficacy and Safety of E6011 in RA Patients with Inadequate Response to Methotrexate

Efficacy and Safety of E6011 in RA Patients with Inadequate Response to Methotrexate

Presented By
Dr Yoshiya Tanaka, University of Occupational and Environmental Health, Japan
Conference
EULAR 2019

Data from a phase 2 study suggests that use of E6011, a new human anti-fractalkine monoclonal antibody, may be beneficial for rheumatoid arthritis (RA) patients with an inadequate response to methotrexate. E6011 led to significant clinical improvements, especially in those with higher CD16+ monocytes. In addition to its efficacy, E6011 was overall well-tolerated in Japanese RA patients naïve to methotrexate.

Fractalkine (CX3CL1) is a chemokine that regulates chemotaxis and cell adhesion of leukocytes expressing the cognate receptor, CX3CR1, during their migration. The serum level of fractalkine is elevated in patients with RA and is linked to disease activity. Peripheral blood CD16+ monocytes and a subset of T cells express CX3CR1, while fractalkine is expressed on fibroblast-like synoviocytes and endothelial cells in the synovial tissue of patients with RA [1].

Dr Yoshiya Tanaka et al. (University of Occupational and Environmental Health, Japan) ev...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on